Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study to Investigate the Safety and Pharmacokinetics of Cemiplimab (Anti-PD-1) and Other Agents in Japanese Patients With Advanced Malignancies

NCT03233139 is registered in ClinicalTrials.gov with Regeneron Pharmaceuticals as lead sponsor.

NCT NCT03233139
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03233139 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study to Investigate the Safety and Pharmacokinetics of Cemiplimab (Anti-PD-1) and Other Agents in Japanese Patients With Advanced Malignancies
Lead sponsor
Regeneron Pharmaceuticals
Phase
Phase 1
Overall status
Active, not recruiting
Start date
June 21, 2017
Completion date
September 30, 2027
Enrollment
146 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignancies